Beraprost sodium, a prostacyclin analog, is a stable and orally active prodrug of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation.
IC50&Target
prodrug of PGI2; Vasodilator
体外研究
Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity. Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment let VE-cadherin at regions of cell–cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions.
体内研究
Beraprost sodium (oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis.
Animal Model:
6-8-week-old C57Bl/6J Male Mice
Dosage:
0.6 mg/kg
Administration:
Oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days
Result:
Mitigated the development of renal interstitial fibrosis.
分子式
C24H29NaO5
分子量
420.47
CAS号
496807-11-5
中文名称
(Rac)-贝拉前列素钠
运输条件
Room temperature in continental US; may vary elsewhere.